The Committee confirmed that Yuviwel will be supplied as a powder and solvent for injection, with multiple dosage options available to clinicians. Achondroplasia, characterized by a specific gene mutation, severely disrupts the development of bones throughout the body, impacting the growth of the skull, spine, and limbs. By targeting the underlying mechanisms of this inherited condition, the treatment offers a new clinical pathway for pediatric patients facing significant skeletal development challenges.
In section Market Quotes
Ascendis Pharma Secures EMA Nod for Achondroplasia Drug Yuviwel
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Yuviwel, an Ascendis Pharma treatment designed to address achondroplasia in children. The decision marks a significant regulatory milestone for the therapy, which aims to mitigate the effects of the genetic disorder.
Comments (0)
No comments yet. Be the first!